$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

$iova Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000114420415063327 Filed on November 06, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.130M	$2.680M	$940.0K
YoY Change	370.64%	185.11%	-56.07%
% of Gross Profit
Research & Development	$3.320M	$4.960M	$354.0K
YoY Change	96.45%	1301.13%	41.6%
% of Gross Profit
Depreciation & Amortization	$310.0K	$266.0K	$5.000K
YoY Change	342.86%	5220.0%
% of Gross Profit
Operating Expenses	$8.450M	$7.643M	$2.803M
YoY Change	73.51%	172.67%	-70.21%
Operating Profit		-$7.643M	-$2.803M
YoY Change		172.67%
Interest Expense	$80.00K	$10.00K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$8.380M	-$7.640M	-$2.800M
YoY Change	72.07%	172.86%	-70.24%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$8.360M	-$7.635M	-$3.014M
YoY Change	79.75%	153.32%	-67.97%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$176.6K	-$161.6K	-$105.1K
COMMON SHARES
Basic Shares Outstanding	47.83M shares	47.19M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$103.7M	$110.1M	$17.20M
YoY Change	130.96%	540.12%	17100.0%
Cash & Equivalents	$33.59M	$30.77M	$17.19M
Short-Term Investments	$70.10M	$79.40M
Other Short-Term Assets	$300.0K	$200.0K	$0.00
YoY Change	200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$104.0M	$110.4M	$17.20M
YoY Change	131.19%	541.81%	17100.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.676M	$1.833M	$200.0K
YoY Change	9.4%	816.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$0.00
YoY Change
Total Long-Term Assets	$1.676M	$1.833M	$200.0K
YoY Change	9.4%	816.5%	100.0%
TOTAL ASSETS
Total Short-Term Assets	$104.0M	$110.4M	$17.20M
Total Long-Term Assets	$1.676M	$1.833M	$200.0K
Total Assets	$105.7M	$112.2M	$17.40M
YoY Change	127.18%	544.97%	8600.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$958.0K	$1.161M	$600.0K
YoY Change	-23.24%	93.5%	-62.5%
Accrued Expenses	$672.0K	$1.608M	$500.0K
YoY Change	104.88%	221.6%	-75.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.630M	$2.855M	$1.300M
YoY Change	-1.93%	119.62%	-62.86%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.630M	$2.855M	$1.300M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.600M	$2.900M	$1.300M
YoY Change	-5.88%	123.08%	-62.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$104.2M	-$95.85M
YoY Change	36.13%
Common Stock	$2.000K	$2.000K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$104.0M	$109.4M	$16.20M
YoY Change
Total Liabilities & Shareholders Equity	$105.7M	$112.2M	$17.40M
YoY Change	127.18%	544.97%	8600.0%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$8.360M	-$7.635M	-$3.014M
YoY Change	79.75%	153.32%	-67.97%
Depreciation, Depletion And Amortization	$310.0K	$266.0K	$5.000K
YoY Change	342.86%	5220.0%
Cash From Operating Activities	-$6.580M	-$3.840M	-$1.730M
YoY Change	98.79%	121.97%	302.33%
INVESTING ACTIVITIES
Capital Expenditures	-$150.0K	-$70.00K	-$160.0K
YoY Change	-89.44%	-56.25%	1500.0%
Acquisitions
YoY Change
Other Investing Activities	-$10.67M	$20.42M
YoY Change
Cash From Investing Activities	-$10.82M	$20.35M	-$160.0K
YoY Change	661.97%	-12818.75%	1500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	280.0K	1.710M	640.0K
YoY Change	-99.14%	167.19%
NET CHANGE
Cash From Operating Activities	-6.580M	-3.840M	-1.730M
Cash From Investing Activities	-10.82M	20.35M	-160.0K
Cash From Financing Activities	280.0K	1.710M	640.0K
Net Change In Cash	-17.12M	18.22M	-1.250M
YoY Change	-161.74%	-1557.6%	184.09%
FREE CASH FLOW
Cash From Operating Activities	-$6.580M	-$3.840M	-$1.730M
Capital Expenditures	-$150.0K	-$70.00K	-$160.0K
Free Cash Flow	-$6.430M	-$3.770M	-$1.570M
YoY Change	240.21%	140.13%	273.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1663000	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10210000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44910000	USD
CY2015Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	20562000	USD
CY2014Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue		USD
CY2015Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	79374000	USD
CY2014Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent		USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	245000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	67000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	110391000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	44977000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1833000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1532000	USD
CY2015Q3	us-gaap	Assets Assets	112224000	USD
CY2014Q4	us-gaap	Assets Assets	46509000	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1161000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1249000	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1608000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	328000	USD
CY2015Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	86000	USD
CY2014Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	86000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2855000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-2798000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19283000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26632908	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43398650	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24107787	shares
	us-gaap	Revenues Revenues		USD
	us-gaap	Revenues Revenues		USD
CY2014Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2449000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	7259000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	6155000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	354000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12147000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1018000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	2803000	USD
	us-gaap	Operating Expenses OperatingExpenses	19406000	USD
	us-gaap	Operating Expenses OperatingExpenses	7173000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2803000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19406000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7173000	USD
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	123000	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	794000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	103000	USD
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	3694	shares
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax		USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	38000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax		USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7597000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2798000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19245000	USD
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3694	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	5694	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5694	shares
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000041666
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000041666
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47807398	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47807398	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33750188	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33750188	shares
CY2015Q3	lbio	Common Stock To Be Issued Shares CommonStockToBeIssuedShares	245153	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2015Q3	lbio	Common Stock To Be Issued Value CommonStockToBeIssuedValue	245000	USD
CY2014Q4	lbio	Common Stock To Be Issued Value CommonStockToBeIssuedValue	245000	USD
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	38000	USD
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	204929000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121161000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95845000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76562000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	109369000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	44846000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	112224000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46509000	USD
CY2014Q4	lbio	Common Stock To Be Issued Shares CommonStockToBeIssuedShares	245153	shares
CY2015Q3	us-gaap	Revenues Revenues		USD
CY2014Q3	us-gaap	Revenues Revenues		USD
CY2015Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2660000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4983000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	7643000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7643000	USD
CY2015Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-7635000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7168000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47271593	shares
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	38000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	992000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	167000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	95236000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-100890000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-167000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	9618000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3002000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	68308000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities		USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	15900000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities		USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7168000	USD
	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	4223000	USD
	lbio	Common Stock Issued Upon Exercise Of Warrants Amount CommonStockIssuedUponExerciseOfWarrantsAmount	9618000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	68308000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1553000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	66000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	691000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	23000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	4223000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1896000	USD
	lbio	Fair Value Of Vested Warrants Granted For Services FairValueOfVestedWarrantsGrantedForServices	1553000	USD
	lbio	Fair Value Of Vested Warrants Granted For Services FairValueOfVestedWarrantsGrantedForServices	825000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	179000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-118000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1193000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1012000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11802000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5318000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	20562000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets		USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	77992000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3002000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-34700000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2483000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19673000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17190000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	66000	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	38000	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1		USD
CY2015Q3	lbio	Working Capital WorkingCapital	107500000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9200000	shares
CY2015Q1	us-gaap	Share Price SharePrice	8.00
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	68300000	USD
CY2014Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6000000	shares
CY2014Q4	us-gaap	Share Price SharePrice	5.75
CY2014Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32200000	USD
CY2013Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	23300000	USD
CY2014Q3	lbio	Reclassification Of Stock Based Compensation Cost ReclassificationOfStockBasedCompensationCost	800000	USD
	lbio	Reclassification Of Stock Based Compensation Cost ReclassificationOfStockBasedCompensationCost	300000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2627000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><b><i>Use of Estimates</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><font style="font-family: 'times new roman', times; font-size: 10pt;"> </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><font style="font-family: 'times new roman', times; font-size: 10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services.</font></p> </div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><b><i>Reclassifications</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><font style="font-family: 'times new roman', times; font-size: 10pt;"> </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><font style="font-family: 'times new roman', times; font-size: 10pt;">In presenting the Company's statement of operations for the three and nine month periods ended September 30, 2014, the Company has reclassified $<font>0.8</font> million and $<font>0.3</font> million, respectively, of stock-based compensation that was previously reflected as operating expenses to research and development expenses. The reclassification relates to stock-based compensation attributable to individuals working in the Company's research and development activities, and had no impact on total costs and expenses, or on net loss.</font></p> </div>
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1635000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><b><i>Concentrations</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><font style="font-family: 'times new roman', times; font-size: 10pt;"> </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><font style="font-family: 'times new roman', times; font-size: 10pt;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and short-term investments.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><font style="font-family: 'times new roman', times; font-size: 10pt;"> </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><font style="font-family: 'times new roman', times; font-size: 10pt;">The Company maintains cash balances at one bank. As of September 30, 2015, the Company's cash balances were in excess of insured limits maintained at this bank. Management believes that the financial institution that hold the Company's cash are financially sound and, accordingly, minimal credit risk exists.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><font style="font-family: 'times new roman', times; font-size: 10pt;"> </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><font style="font-family: 'times new roman', times; font-size: 10pt;">At September 30, 2015, the Company's short-term investments were invested in short-term fixed income debt securities of domestic and foreign high credit issuers and in money market funds. The Company's investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. At September 30, 2015, approximately <font>56</font>% of the Company's short-term investments were invested in notes of five companies, <font>25</font>% were invested in notes of various domestic issuers, and <font>19</font>% were invested in notes of a foreign issuers. The average maturity of these notes was 66 days (See Note 3).</font></p> </div>
	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	2387000	USD
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	940000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	5776000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	2722000	USD
CY2015Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	79374000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities		USD
CY2015Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	110146000	USD
CY2014Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	45000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.84
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	233499	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	4.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	30000	shares
CY2015Q3	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	3104000	USD
	us-gaap	Trading Securities Unrealized Holding Gain TradingSecuritiesUnrealizedHoldingGain	38000	USD
	us-gaap	Trading Securities Unrealized Holding Loss TradingSecuritiesUnrealizedHoldingLoss		USD
CY2015Q3	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	99936000	USD
CY2015Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	99936000	USD
	us-gaap	Depreciation Depreciation	691000	USD
CY2014Q3	us-gaap	Depreciation Depreciation	5000	USD
	us-gaap	Depreciation Depreciation	23000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	757500	shares
CY2015Q3	us-gaap	Depreciation Depreciation	266000	USD
CY2015Q3	us-gaap	Trading Securities Cost TradingSecuritiesCost	99897000	USD
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	1000000	shares
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	2000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	8.24
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	494001	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.56
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Lion Biotechnologies, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001425205
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47833934	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
CY2015Q3	us-gaap	Recorded Unconditional Purchase Obligation Due In Second Year RecordedUnconditionalPurchaseObligationDueInSecondYear	2874000	USD
CY2015Q3	us-gaap	Recorded Unconditional Purchase Obligation RecordedUnconditionalPurchaseObligation	5978000	USD
	us-gaap	License Costs LicenseCosts	2500000	USD
	us-gaap	License Costs LicenseCosts	900000	USD
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><b><font style="text-decoration: underline;">NOTE 8. LEGAL PROCEEDINGS</font></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in;">On August 18, 2015, MBA Holdings, LLC filed a breach of contract lawsuit against the Company in the Superior Court of California, County of Los Angeles (MBA Holdings, LLC v. Lion Biotechnologies, Inc., Case BC 591513). The complaint alleges that the Company and MBA Holdings, LLC were parties to (i) a June 15, 2012 Finder's Fee Agreement, (ii) a Confidentiality, Non-Disclosure and Non-Circumvention Agreement, dated June 13, 2012, and (iii) a Consulting Agreement, dated July 9, 2012, and that the Company breached these agreements by failing to compensate MBA Holdings for introducing Roth Capital Partners, LLC and Highline Research Advisors LLC to the Company in connection with the $<font>23.3</font> million equity funding the Company completed in November 2013. MBA Holdings also alleges that the Company failed to register certain shares underlying a common stock purchase warrant that the Company issued to MBA Holdings. MBA Holdings has asked for damages in the amount of $<font>7,746,000</font>. The Company has not yet been served in the foregoing lawsuit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in;">The Company believes that there is no merit to the claims made by MBA Holdings in the complaint. On September 9, 2015 the Company provided MBA Holdings with evidence that the Company dealt with a certain investment banker on a financing transaction at least six months before MBA Holdings purportedly introduced the Company to the banker, and that a certain research analyst group were known to the Company prior to the purported introduction. Accordingly, the Company has demanded that MBA Holdings dismiss the lawsuit. To date, MBA Holdings has not served the complaint on the Company, dismissed the lawsuit, or responded to the Company's last communications. Accordingly, on October 26, 2015 the Company renewed its demand on MBA and its counsel to dismiss the suit or face exposure to damages for malicious prosecution, voluntarily entered an appearance in the case, and initiated discovery proceedings for the purpose of pursuing an early resolution of the case in the Company's favor. The Company intends to vigorously defend itself in this matter and will seek a prevailing-party award of its attorney's fees and other litigation costs pursuant to contractual provisions in the agreements appended to MBA's complaint. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">There are no other pending legal proceedings to which the Company is a party or of which its property is the subject other than as previously reported.</p></div>
	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	7746000	USD

Files In Submission

Name	View Source	Status
0001144204-15-063327-index-headers.html	Edgar Link	pending
0001144204-15-063327-index.html	Edgar Link	pending
0001144204-15-063327.txt	Edgar Link	pending
0001144204-15-063327-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
lbio-20150930.xml	Edgar Link	completed
lbio-20150930.xsd	Edgar Link	pending
lbio-20150930_cal.xml	Edgar Link	unprocessable
lbio-20150930_def.xml	Edgar Link	unprocessable
lbio-20150930_lab.xml	Edgar Link	unprocessable
lbio-20150930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v423195_10q.htm	Edgar Link	pending
v423195_ex10-47.htm	Edgar Link	pending
v423195_ex31-1.htm	Edgar Link	pending
v423195_ex31-2.htm	Edgar Link	pending
v423195_ex32-1.htm	Edgar Link	pending
v423195_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

2015 Q4 Form 10-Q Financial Statement

#000114420415063327 Filed on November 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IOVA IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

2015 Q4 Form 10-Q Financial Statement

#000114420415063327 Filed on November 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova